Previous Close | 41.21 |
YTD Return | N/A |
Expense Ratio (net) | 0.00% |
Category | N/A |
Last Cap Gain | N/A |
Morningstar Rating | ★★★★★ |
Morningstar Risk Rating | Above Average |
Sustainability Rating |
Net Assets | N/A |
Beta (5Y Monthly) | 1.03 |
Yield | 0.00% |
5y Average Return | N/A |
Holdings Turnover | 32.61% |
Last Dividend | N/A |
Average for Category | N/A |
Inception Date | Jun 24, 2019 |
Initiated Next Phase of European Expansion Strategy with First National Reimbursement in Sweden Market Access Negotiations and Launch Preparations for VAZKEPA Underway Across Multiple European Markets Continued Progress on Go-To-Market Strategy in the US Plans for Regulatory Filings for Approval of VASCEPA® (icosapent ethyl) in Several Additional Countries in 2022 Company to Host Conference Call Today at 8:00 a.m. ET DUBLIN, Ireland and BRIDGEWATER, N.J., May 04, 2022 (GLOBE NEWSWIRE) -- Amarin
DUBLIN, Ireland and BRIDGEWATER, N.J., April 19, 2022 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that it will host a conference call with members of Amarin’s senior management team to discuss the Company's first quarter 2022 financial results on Wednesday, May 4, 2022 at 8:00 a.m. ET. The conference call will follow the anticipated release of the Company's financial results earlier that day. Conference Call and Webcast Information:Access to live call:Go to the inves